Your browser doesn't support javascript.
loading
"Anti-obesity medications" or "medications to treat obesity" instead of "weight loss drugs" - why language matters - an official statement of the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO) and the Brazilian Society of Endocrinology and Metabolism (SBEM).
Halpern, Bruno; Mancini, Marcio C; van de Sande-Lee, Simone; Miranda, Paulo Augusto Carvalho.
Afiliação
  • Halpern B; Associação Brasileira para o Estudo da Obesidade e Síndrome Metabólica, São Paulo, SP, Brasil.
  • Mancini MC; Departamento de Obesidade, Sociedade Brasileira de Endocrinologia e Metabologia, São Paulo, SP, Brasil.
  • van de Sande-Lee S; Centro de Obesidade, Hospital 9 de Julho, São Paulo, SP, Brasil.
  • Miranda PAC; Departamento de Obesidade, Sociedade Brasileira de Endocrinologia e Metabologia, São Paulo, SP, Brasil.
Arch Endocrinol Metab ; 67(4): e230174, 2023 Aug 16.
Article em En | MEDLINE | ID: mdl-37585688
ABSTRACT
Obesity is largely undertreated, in part because of the stigma surrounding the disease and its treatment. The use of the term "weight loss drugs" to refer to medications for the treatment of obesity may contribute to this stigma, leading to the idea that anyone who wants to lose weight could use them and that short-term use, only in the active weight loss phase would be enough. On the contrary, the use of terms such as "medications to treat obesity" or "anti-obesity medications" conveys the idea that the treatment is directed at the disease rather than the symptom. This joint statement by the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO) and the Brazilian Society of Endocrinology and Metabolism (SBEM) intends to alert the press, healthcare professionals and scientific community about the importance of the appropriate use of language, with the aim of improving obesity care.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fármacos Antiobesidade / Síndrome Metabólica Tipo de estudo: Guideline / Risk_factors_studies Limite: Humans País/Região como assunto: America do sul / Brasil Idioma: En Revista: Arch Endocrinol Metab Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Brasil

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fármacos Antiobesidade / Síndrome Metabólica Tipo de estudo: Guideline / Risk_factors_studies Limite: Humans País/Região como assunto: America do sul / Brasil Idioma: En Revista: Arch Endocrinol Metab Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Brasil